You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – Agios submitted a supplemental new drug application on Monday to the US Food and Drug Administration for ivosidenib (Tibsovo) to treat IDH1-mutated bile duct cancer.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.